A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

February 8, 2023

Study Completion Date

June 29, 2023

Conditions
COVID-19
Interventions
DRUG

EDP-235

capsule

DRUG

Placebo

capsule

Trial Locations (23)

28150

Carolina Research Center, Shelby

33021

Universal Medical and Research Center, LLC, Hollywood

33143

USPA Advance Concept Medical Research Group. LLC, Miami

33144

Continental Clinical Research, LLC, Miami

Dynamic Medical Research, LLC - Miami, Miami

33155

D&H National Research Centers, Miami

Florida International Medical Research, Miami

33166

Doral Medical Research, Doral

33176

Reed Medical Research, Miami

33180

MedBio Trials - Miami, Aventura

34142

Advanced Research for Health Improvement, LLC, Immokalee

43617

Toledo Institute of Clinical Research, Toledo

75149

SMS Clinical Research, LLC, Mesquite

75154

Epic Medical Research, Red Oak

90057

LA Universal Research Center, Inc., Los Angeles

90717

Torrance Clinical Research Institute, Lomita

400347

County Emergency Hospital, Cluj-Napoca

33021-6467

Encore Medical Research - Hollywood, Hollywood

33126-1921

LCC Medical Research - Miami - ClinEdge - PPDS, Miami

33155-6542

BioClinical Research Alliance, Miami

33174-2968

C'A Medical Center Inc Research, Miami

34952-7536

CDC Research Institute, LLC, Port Saint Lucie

77008-1393

Trio Clinical Trials LLC, Houston

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT05616728 - A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 | Biotech Hunter | Biotech Hunter